Acalabrutinib [1420477-60-6]
Référence HY-17600-10mg
Conditionnement : 10mg
Marque : MedChemExpress
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
Acalabrutinib Chemical Structure
CAS No. : 1420477-60-6
This product is a controlled substance and not for sale in your territory.
Based on 21 publication(s) in Google Scholar
Other Forms of Acalabrutinib:
- Acalabrutinib-d4 Obtenir un devis
- (R)-Acalabrutinib Obtenir un devis
- Acalabrutinib-d3 Obtenir un devis
- Acalabrutinib (Standard) Obtenir un devis
| Description |
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL)[1][2]. Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. |
IC50 & Target |
IC50: 3 nM (BTK in CD69 B cell)[2] |
||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cellular Effect |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| In Vitro |
Acalabrutinib (ACP-196) inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT, in the in vitro signaling assay on primary human CLL cells. In the human CLL NSG xenograft model, Acalabrutinib demonstrates on-target effects including decreased phosphorylation of PLCγ2, ERK and significant inhibition of CLL cell proliferation[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||||||||||||||||||||||||||||||||
| In Vivo |
Acalabrutinib (100 mg twice per day) assessed for thrombus formation at injured arterioles of the mice, exhibits more selective for inhibiting BTK and has virtually no inhibition of platelet activity[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Essai clinique |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Masse moléculaire |
465.51 |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Formule |
C26H23N7O2 |
||||||||||||||||||||||||||||||||||||||||||||||||||
| CAS No. |
1420477-60-6 |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Appearance |
Solid |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Color |
Off-white to light brown |
||||||||||||||||||||||||||||||||||||||||||||||||||
| SMILES |
O=C(NC1=NC=CC=C1)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]5N(C(C#CC)=O)CCC5)=N3)C=C2 |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Livraison | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Stockage |
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Solvant et solubilité |
In Vitro:
DMSO : 116.67 mg/mL (250.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Pureté et documentation |
Purity: 99.88%
SDS (393 KB)
COA (251 KB) HNMR (307 KB) LCMS (99 KB) Elemental Analysis Report (109 KB) Instruction de manipulation (2659 KB) |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Références |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 2.1482 mL | 10.7409 mL | 21.4818 mL | 53.7045 mL |
| 5 mM | 0.4296 mL | 2.1482 mL | 4.2964 mL | 10.7409 mL | |
| 10 mM | 0.2148 mL | 1.0741 mL | 2.1482 mL | 5.3705 mL | |
| 15 mM | 0.1432 mL | 0.7161 mL | 1.4321 mL | 3.5803 mL | |
| 20 mM | 0.1074 mL | 0.5370 mL | 1.0741 mL | 2.6852 mL | |
| 25 mM | 0.0859 mL | 0.4296 mL | 0.8593 mL | 2.1482 mL | |
| 30 mM | 0.0716 mL | 0.3580 mL | 0.7161 mL | 1.7902 mL | |
| 40 mM | 0.0537 mL | 0.2685 mL | 0.5370 mL | 1.3426 mL | |
| 50 mM | 0.0430 mL | 0.2148 mL | 0.4296 mL | 1.0741 mL | |
| 60 mM | 0.0358 mL | 0.1790 mL | 0.3580 mL | 0.8951 mL | |
| 80 mM | 0.0269 mL | 0.1343 mL | 0.2685 mL | 0.6713 mL | |
| 100 mM | 0.0215 mL | 0.1074 mL | 0.2148 mL | 0.5370 mL |
Acalabrutinib Related Classifications
- Protein Tyrosine Kinase/RTK
- Btk